BRIEF — Mylan exercises option to acquire Aspen Australasian portfolio

Netherlands-incorporated drugmaker Mylan has exercised an option from a 2018 distribution agreement to acquire a portfolio of prescription and over-the-counter products from Aspen Pharmacare in, primarily, Australia and New Zealand.

The total value of the acquisition could reach A$188 million ($130 million), partly contingent on the South African drugmaker satisfying certain
conditions.

Aspen still has a strong presence in both developed and emerging markets, but has previously announced that the group would divest of non-core assets.